secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERACYTE, INC. (VCYT)
CIK:        0001384101
Form:       8-K
Filed at:   2022-11-02T23:59:59+00:00
Accession:  0001384101-22-000137
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veracyte Q3 revenue up 25% to $75.6M; net loss improves 38%
-----------------------------------------------------------

- Total revenue $75.6M (+25% YoY), test volume 26,374 (+26% YoY).
- Net loss $8.7M improves 38% YoY; diluted EPS -$0.12 improves 40% YoY.
- Non-GAAP gross margin 66% vs 64% prior year; operating cash flow $7.0M in Q3.
- Decipher Prostate gets NCCN Level 1 evidence; commercial coverage expanded to 195M lives for Decipher, 230M for Afirma.
- Ended Q3 with $170.1M cash; appointed Dr. Eliav Barr to board, John Leite as GM Pulmonology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1384101/000138410122000137/0001384101-22-000137-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1384101/000138410122000137/vcyt-20221102.htm
  HTML page:      https://secwatch.observer/filing/0001384101-22-000137

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer